반응식
[Cl:1][C:2]1[CH:7]=[C:6]([Cl:8])[CH:5]=[CH:4][C:3]=1[S:9]([N:12]([CH2:14][C:15]1[O:19][CH:18]=[C:17]([C:20](O)=[O:21])[CH:16]=1)[CH3:13])(=[O:11])=[O:10].C1N=CN(C(N2C=NC=C2)=O)C=1.[NH:35]1[CH2:39][CH2:38][N:37]=[C:36]1[C:40]1[CH:45]=[CH:44][C:43]([CH2:46][CH2:47][NH:48][CH3:49])=[CH:42][CH:41]=1.Cl>ClCCCl>[Cl:1][C:2]1[CH:7]=[C:6]([Cl:8])[CH:5]=[CH:4][C:3]=1[S:9]([N:12]([CH2:14][C:15]1[O:19][CH:18]=[C:17]([C:20]([N:48]([CH2:47][CH2:46][C:43]2[CH:42]=[CH:41][C:40]([C:36]3[NH:37][CH2:38][CH2:39][N:35]=3)=[CH:45][CH:44]=2)[CH3:49])=[O:21])[CH:16]=1)[CH3:13])(=[O:10])=[O:11]참가 물질
6
반응물 4
생성물 1
시약·촉매·용매 1
실험 절차
5-({[(2,4-dichlorophenyl)sulfonyl](methyl)amino}methyl)furan-3-carboxylic acid (34 mg, 0.08 mmol) was dissolved in DCE (1 mL) and CDI (26 mg, 0.16 mmol) was added. The reaction was stirred for 2 h. The activated acid solution in DCE was added to a vial containing 2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-N-methylethanamine.HCl (43 mg, 0.16 mmol) and TEA (0.022 mL, 0.16 mmol). The reaction was stirred at ambient temperature for 18 h, then partitioned between saturated aqueous NaHCO3 (1 mL) and DCE (3×1 mL)). The organic layer was dried over MgSO4 and solvents were removed in vacuo. A portion of the crude product was purified by prep method A.
후처리
- stirringThe reaction was stirred at ambient temperature for 18 h
- custompartitioned between saturated aqueous NaHCO3 (1 mL) and DCE (3×1 mL))
- dry with materialThe organic layer was dried over MgSO4 and solvents
- customwere removed in vacuo
- customA portion of the crude product was purified by prep method A
출처 및 근거
- ORD 기록
- ord-f0da3c52aec746758d726e76ec0b00ab
- 출처 데이터셋
- uspto-grants-2014_01
- 특허 번호
- US08623859B2
연결된 노트
불러오는 중…